Boehringer Sued Over $120M Pay-For-Delay On Stroke Drug

A great stroke association would know all about drugs for stroke and when they come off patent and make sure no hanky-panky is occurring.
http://www.law360.com/articles/488020/boehringer-sued-over-120m-pay-for-delay-on-stroke-drug
Miami-Luken Inc., a wholesaler to pharmacies, accused Boehringer Ingelheim Pharmaceuticals Inc. of orchestrating a $120 million pay-for-delay deal to keep generic versions of its stroke prevention medication off the market, according to a putative class action filed in Pennsylvania federal court Friday.

Miami-Luken says it has been buying Boehringer’s Aggrenox at artificially inflated prices because Boehringer paid off a potential competitor in 2008, agreeing to give it a share of Aggrenox’s profits in exchange for delaying sale of the generic for seven years.

Miami-Luken alleges that...

To view the full article, take a free trial now.

Already a subscriber? Click here to login

Case Information

Case Title

MIAMI-LUKEN, INC. v. BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG et al

Case Number

2:13-cv-06543

Court

Pennsylvania Eastern

Nature of Suit

410(Other Statutes: Anti-Trust)

Judge

HONORABLE MITCHELL S. GOLDBERG

Date Filed

November 8, 2013

Sections

• Class Action
• Competition
• Intellectual Property
• Life Sciences
• Pennsylvania

Law Firms Mentioned

• Garwin Gerstein
• Heim Payne
• Levin Fishbein

Companies Mentioned

• Boehringer Ingelheim
• Teva Pharmaceutical Industries Limited (NASDAQ:TEVA)

Government Agencies Mentioned

• Federal Trade Commission
• Food and Drug Administration

Related Articles

• Barr Settles Mirapex, Aggrenox Patent Suits
• FTC Wants Access To Boehringer Docs In Pay-For-Delay Probe
• DC Circ. Won't Kill FTC Bid For Boehringer Deal Docs
• FTC Accuses Boehringer Of Subpoena Delay Tactics
• FTC, Boehringer Wrangle Over Generics Settlement Docs